What is Pfizer's stock-based comp?

Pfizer (PFE) reported stock-based comp of $272M in Q1 2026.

How has Pfizer's stock-based comp changed year-over-year?

Pfizer's stock-based comp increased by 60.0% year-over-year, from $170M to $272M.

What is the long-term trend for Pfizer's stock-based comp?

Over 4 years (2021 to 2025), Pfizer's stock-based comp has grown at a -9.3% compound annual growth rate (CAGR), from $1.18B to $799M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Pfizer PFE Stock-Based Comp

Stock-Based Comp at other companies

Bristol-Myers SquibbBMY

$146M+1.4%

Eli LillyLLY

$161M+4.5%

Johnson & JohnsonJNJ

$300M+4.2%

Merck & Co.MRK

$185M-5.1%

AmgenAMGN

$75M-11.8%

Ionis PharmaceuticalsIONS

$43.28M+45.6%

Other financials

Income statement

See full

Revenue$14.5B+5.4%

Gross profit$10.9B+0.3%

Net income$2.7B-9.4%

EPS (diluted)$0.47-9.6%

Balance sheet

See full

Cash & equivalents$1.8B+18.8%

Total debt$64.4B+4.9%

Total equity$90.1B-0.3%

Total assets$207.62B-0.2%

Cash flow

See full

Operating cash flow$2.6B+12.0%

CapEx$436.0M-22.7%

Free cash flow$2.2B+23.0%

Valuation

See full

Market cap$138.44B+0.2%

Enterprise value$201.11B+1.4%

P/E11.4×—

P/S2.2×0.0×

Profitability

See full

Gross margin73.5%+1.2pp

Net margin15.7%—

FCF margin18%+8.8pp

Returns & leverage

See full

Return on equity10.6%—

Debt / equity0.7×0.0×

Current ratio1.2×0.0×

Where this comes from

Reported directly by Pfizer in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Pfizer’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pfizer's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pfizer's stock-based comp?: Pfizer (PFE) reported stock-based comp of $272M in Q1 2026.
How has Pfizer's stock-based comp changed year-over-year?: Pfizer's stock-based comp increased by 60.0% year-over-year, from $170M to $272M.
What is the long-term trend for Pfizer's stock-based comp?: Over 4 years (2021 to 2025), Pfizer's stock-based comp has grown at a -9.3% compound annual growth rate (CAGR), from $1.18B to $799M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.